IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
AssigneeThe Cleveland Clinic Foundation
InventorsQing Yi, Yong Lu
Life of this patent
Estimating the term…
Abstract
A method of producing a population of CD8+ Tc9 lymphocytes is provided including priming a population of naïve CD8+ T cells by contacting the population of naïve CD8+ T cells with an immunogenic peptide, in the presence of a Tc9 supportive environment, thereby producing a population of CD8+ Tc9 lymphocytes which secrete IL-9. Purified populations of CD8+ Tc9 cells are also disclosed herein, as are method for their use in the treatment of cancer in a subject.
Claims11
A method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a population of CD8+ Tc9 cells and a pharmaceutically acceptable carrier, wherein the population of CD8+ Tc9 cells secretes IL-9, wherein the CD8+ Tc9 cells are produced by priming a population of naïve CD8+ T cells by contacting the population of naïve CD8+ T cells with an immunogenic peptide, in the presence of a first Tc9 supportive environment, thereby producing a population of CD8+ Tc9 lymphocytes which secrete IL-9, wherein the first Tc9 supportive environment comprises at least one Tc9 polarizing cytokine or agent selected from the group consisting of IL-4, TGF-β, INF-γ neutralizing agent and IL-12 neutralizing agent.
Dependencies are inferred from the claim text.